Theolytics is developing a pipeline of best-in-class oncolytic immunotherapies
Our discovery programmes begin with candidate selection in actual patient tumours with an intact tumour micro-environment. The Theolytics approach focuses on not only killing cancer cells, but also in destroying the surrounding tumour microenvironment, a significant yet often overlooked barrier in the development of anti-cancer medicines. Our candidates trigger immunogenic cell death and promote T-cell activation. We are pioneering new delivery approaches to develop efficacious, targeted candidates suitable for direct and intravenous delivery.
Innovation - Pipeline
THEO-260 is a novel oncolytic immunotherapy specifically evolved to target stromal-rich tumours. It has three critical modes of action which together enable it to tackle the complex, immune-suppressed nature of advanced solid tumours.
-
Direct killing of cancer-associated fibroblasts
-
Direct killing of cancer cells
-
Triggers immunogenic cell death, and promotes T-cell activation
TECHNOLOGY
>100 million possibilities for transformative therapies
Less than 1% of the adenovirus product landscape has been explored to date. Our proprietary libraries unlock the full potential of this modality; hundreds of millions of possibilities for therapies across a diverse range of applications spanning oncology, gene therapy and infectious disease.
TECHNOLOGY
Selection systems optimised for translational success
Advanced bioselection and screening systems enable the identification of therapies:
-
representing a step-change in clinical efficacy potential
-
optimised for safe, targeted administration
-
enhanced for manufacture, yield and stability
